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Abstract
Background: The role of IL-1β, PGE2 and MMP-3 in the pathogenesis of periodontal disease is well researched. This study aimed 
to asses and compared the salivary IL-1β, PGE2 and MMP-3 levels in patients with untreated chronic severe periodontitis and those 
treated with periodontal phase I therapy and periodontally healthy individuals as controls, in relationship to the presence of salivary 
anti-β1 IgA.
Methods: A total of 30 subjects participate in the study: 15 subjects had chronic severe periodontitis and 15 were healthy individuals 
used as a control. After saliva collection and its purification, we quantify by enzyme-linked immunosorbent assay (ELISA) procedure 
using as coating antigen a synthetic β1 peptide with an amino acid sequence identical to the second extracellular loop of the human β1 
adrenoceptor (β1 AR), the presence of anti β1 AR antibody (IgA) in the saliva of patients and healthy individuals. Also, IL-1β, PGE2, 
nitrites and metalloproteinase 3 (MMP-3) were assessed using ELISA) assay.
Results: Our data indicated that IL-1β, PGE2, nitrites and MMP-3 levels are elevated in the saliva of patients with untreated 
chronic severe periodontitis and were significantly higher than in healthy subjects. Also, the amounts of anti- β1 IgA in the saliva 
was significantly higher compared with that of healthy individuals. After periodontal phase I therapy these levels of inflammatory 
biomarkers are significantly reduced but the titres of the antibody did not change, suggesting a close association between salivary IL-
1β, PGE2, nitrites and MMP-3 and periodontitis without any changes in the levels of anti β1 IgA.
Conclusions: These results suggest that the abnormal amount of these cytokines and enzymes in saliva has potential monitoring 
applications as a risk marker of the disease progression but the raised levels of anti β1 IgA present in the saliva of chronic severe 
periodontitis patient, are not directly associated with the course of the disease. Additional studies are needed to validate this 
assumption.
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Introduction
Periondontal disease is a chronic microbial and inflammatory 
process characterized by the presence of sulcular pathogenic 
bacteria, impaired host immune response, destruction of the 
connective tissue involved in tooth attachment, and resorption 
of alveolar bone. Bacterial pathogens are required to initiate 
the disease process [1-3]. 
Circulating substances have been detected at elevated levels 
in gingival crevicular fluid and whole saliva of patients who 
have periodontal disease, making them putative biomarkers of 
the disease [4-6]. Periodontal pathogens activate host cells to 
produce pro-inflammatory mediators [7,8] and cytoplasmatic 
enzymes [9], which, in turn, promote the destruction of 
periodontal tissues. The release of the inflammatory cytokine, 
IL-1β, PGE2 and lysosomal and cytoplasmic enzymes, such as 
metalloproteinases (MMPs), to periodontal tissues is higher 
in the areas with inflammation [10,11]. In addition, various 
enzymes, cytokines and biomarkers of bone turnover have been 
found to be elevated in the saliva of periodontitis patients in 
comparison with periodontally healthy controls [12-14].
Recently, we reported that in the sera of periodontitis patients 
we found autoantibodies against atria cardiac β1-adrenoreceptor 
(anti-β1-AR IgG) that were able to mimic the effect of an 
authentic β1-AR agonist acting on atria β1-AR [15,16]. However, 
the release of host-derived inflammatory mediators, such as 
cytokines from chronically inflamed periodontal tissues, into the 
circulation together with the sera anti-β1-AR IgG, may provide 
a link between periodontal disease and cardiovascular disease 
[17,18]. Moreover, the effect of anti-β1-AR IgG acting on β1-
AR in rat atria and its capacity to activate caspase pathway, 
molecular signals involved in anti-β1-AR IgG - β1-AR-stimulated 
myocardium apoptosis and increased cAMP production and JNK 
phosphorylation, and the role of anti-β1-AR IgG in the release 
of inflammatory mediators (PGE2, NO, cGMP) that participate 
in atria β1-AR-stimulated cardiomyocytes apoptosis were also 
determined [19].
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Based on these observations, we considered it of special 
relevance to investigate whether salivary secretory IgA (anti-β1 
IgA) from patients with chronic severe periodontitis could 
be a new marker of the pathosiological event that occurs 
in this disease in relationship with host-derived enzymes 
(MMPs), cytokines (IL-1β) and PGE2 present in the saliva of 
the untreated periodontitis patients and those treated with 
periodontal phase I therapy in its.
Materials and methods
Patients
The patients in this study were 40 to 60 year-old, non-smoker 
males being treated in the Department of Periodontics, School 
of Dentistry, University of Buenos Aires.
Thirty patients with pre-existing chronic severe periodontitis 
were included in the test group before and after conventional 
periodontal I therapy. The assessment of clinical parameters was 
carried out by a trained periodontist following criteria based 
on clinical parameters and the severity of periodontal tissue 
destruction [20]. The characteristic clinical signs of periodontitis 
included loss of clinical attachment, horizontal and/or angular 
alveolar bone loss, periodontal pocket formation, and gingival 
inflammation. To be included in the study, at least six sites 
with ongoing periodontal disease were required. Clinical 
measurements in patients with periodontitis included sites 
with alveolar bone loss>2mm and a pocket depth>5 mm with 
bleeding and attachment loss>3 mm. No subject (periodontal 
patient or healthy individual) had any systemic illness and 
they were all never-smokers. Patients with periodontitis had 
Characteristics Healthy subjects 
(control) (n=15)
Chronic Periodontitis Patients 
(n=15)
Before 
Treatment
After 
Treatment
Age (years, SD) 49.6±5.2 47.9±5.6 47.5±5.4
Male (%) 80 75 75
Smoking
(non-smoker/smoker)
0/12 0/15 0/15
CAL ≥ 2 mm (%, SD) 0 80.54±12.31 60.33±11.16*
PD ≥ 4 (%, SD) 0 69.40±15.91 47.96±17.71**
BOP (%, SD) 5.37±1.65 88.44±10.76 75.42±10.26
PI (SD) 1.10±0.51 6.14±0.48 2.28±0.38**
GI (SD) 0.55±0.25 1.46±0.18 1.40±0.21
All patients and healthy individuals had at least 20 teeth and no 
systemic diseases. Values expressed the means±SD of fifteen patients 
and fifteen healthy normal subjects. CP: chronic Periodontitis; 
CAL: clinical attachment level; PD: probing depth; BOP: bleeding 
on probing; PI: periodontal index; GI: gingival index; SD: standard 
desviation. Mann-Whitney U-test was applied and differences were 
considered statistically significant when P<0.05. *P<0.001 comparing 
CP after versus CP before treatment; **P<0.001 comparing CP after 
versus CP before treatment.
Table 1. Comparison of the Clinical Parameters of the CP patients 
with or without Conventional Periodontal Treatment.
not received periodontal treatment or antibiotics within the 
preceding 5 months or any anti-inflammatory drug within 
3 weeks prior to the study. The clinical characteristics of the 
study population and the healthy subjects (controls) are 
shown in (Table 1).
The control group consisted of thirty healthy non-smoker 
volunter males of the same age range, and with a clinically 
healthy periodontium from the same department. In the 
healthy subjects (control group), the probing depth was<3 
mm and the attachment loss was<2 mm. Moreover, probing 
pocket depth and clinical attachment level were assessed 
at six sites per tooth and bleeding on probing at four sites 
per tooth. This group had<10% of sites with bleeding on 
probing (BOP), no sites with probing depth (PD)≥4 mm, no 
clinical attachment loss (AL), <2 mm, and no radiographic 
evidence of bone loss.
Exclusion criteria were individuals who had undergone 
periodontal treatment in the last 6 months; history of 
medications including antibiotics and anti-inflammatory 
drugs in the last 6 months; history of any systemic disease; 
and detection of any obvious oral mucosal lesion.
This study was approved by the Ethical Commission of the 
School of Dentistry, University of Buenos Aires. Written informed 
consent was obtained from each participant in this study, which 
was conducted under the rules of the Helsinki Declaration. 
Saliva collection
Participants were instructed to refrain from eating, drinking 
and practicing oral hygiene procedures 12 hours before 
saliva collection. Whole unstimulated saliva was collected 
early morning after fasting (8 hours) from all patients 
by expectoration into sterile bulbs. The total amount of 
saliva collected was 1 ml. Collected samples were placed 
immediately on ice and transported to the laboratory, where 
they were centrifuged at 5,000 g for 10 minutes, and the clear 
supernatants were stored in aliquots at –80ºC in presence of 
protease inhibitors. The samples were thawed and the assays 
were performed with in 2 months of collection. 
Clinical parameters
Clinical data included: CAL: clinical attachment level; PD: 
probing depth; BOP: bleeding on probing; PI: periodontal 
index; GI: gingival index (Table 1). The index measurements 
were done at six sites per tooth (mesio-buccal, mid-buccal, 
disto-buccal, disto-lingual, mid-lingual and mesio-lingual) 
and CAL was obtained by measuring only interproximal sites. 
These data were recorded and the treatment was performed 
by a trained periodontist. The data were recorded after saliva 
sample collection.
Periodontal therapy
Periodontal phase I therapy (PPIT) consisted of full-mouth 
scaling, root planning and oral hygiene instructions. Only 
the patients with periodontitis received PPIT after saliva 
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sample collection and clinical measurements of baseline. 
The therapy was completed in two visits, each one week 
apart. No antibiotics were prescribed after the treatment. The 
patients were re-evaluated for clinical parameters one month 
afterwards and saliva samples were taken again. 
Purification of saliva IgA
The IgA fractions of 15 patients with chronic periodontitis 
untreated and treated with PPIT and 15 healthy individuals 
were independently purified by standard diethylaminoethyl 
cellulose (DEAE) chromatography. Briefly, saliva samples were 
dialyzed against 0.01 M phosphate buffer, pH 8.0, for 18 hours 
and then applied to DEAE cellulose columns equilibrated in 
the same buffer. The pass-through IgG-rich fractions were 
discarded and IgA-rich fractions were eluted with 0.05 M NaCl 
in 0.01 M phosphate buffer, pH 8. The IgA concentration in the 
enriched fractions was quantificated by radial immunodiffusion 
method after concentration by ultrafiltration with PM-30 
filtering membranes (Amicon, Beverly, MA, USA) (cutoff 
molecular weight, 30,000 Da). The concentration of IgA was 
35.8±15.2 mg/dl in the IgA-enriched fractions. IgA was also 
purified by affinity chromatography of different saliva on 
Jacalin agarose beads following the recommendations of the 
supplier (ICN Pharmaceuticals, Irvine, CA, USA) and previously 
described methods [21].
ELISA procedure
Fifty microliters of synthetic β1 peptide solution (20 μg/ml) 
in 0.1 M Na2CO3 buffer, pH 9.6, was used to coat microtiter 
plates (NUNC, Kastrup, Denmark) at 4°C overnight.
After blocking the wells, diluted sera from patients with 
chronic severe periodontitis and healthy individuals (control) 
were added in triplicate and allowed to react with the peptide 
for 2 hours at 37°C. After the wells were thoroughly washed 
with 0.05% Tween 20 in phosphate buffered solution (PBS) 
100 μl of 1:6000 biotinylated goat anti-human IgA antibodies 
(Sigma Chemical Co., St. Louis, MO, USA) was added and 
incubated for 1 hour at 37°C. Then, a 1:6000 dilution of 
extravidin-alkaline phosphatase (Sigma) was allowed to 
react an extra 30 minutes at 37°C. After extensive washings, 
p-nitrophenylphosphate (1 mg/ml) was added as the substrate, 
and the reaction was stopped at 30 minutes. Finally, the plates 
were read at 405 nm and the results for each sample were 
Group Basal salivary 
flow (ml/10 min)
Total IgA 
(μg/ml)
IgA1
 (μg/ml)
IgA2 (μg/ml)
Periodontitis 
patients
1.2±0.6* 164±19 66±5*  98±8*
Healthy subjects 9.7±3.5 180±22 72±6 108±9
Table 2. Salivary flow, total IgA and subclasses of IgA  
(IgA1 and IgA2).
Values represent the means±SEM of 15 patients and 15 healthy 
normal subjects. *P<0.0001 comparing with healthy subjects.
expressed as the means and SD of triplicate values.
Biomarker analysis
Concentration of salivary IL-1β (pg/ml), PGE2 (ng/ml), nitrites 
(μM) and MMP-3 (ng/ml) were determined in duplicate using 
ELISA assay for each patient and the healthy individuals of 
the human colorimetric immunoreactive kits from Cayman 
Chemical (Ann Arbor, MI, USA), respectively.
Drugs
The synthetic β1 peptide corresponded to the sequence of 
the second extracellular loop of the human β1-AR (H-W-W-R-
A-E-S-D-E-A-R-R-C-Y-N-D-P-K-C-C-D-F-V-T-N-R-C) and a 27-mer 
non-related peptide S-G-S-G-S-G-S-G-S-G-S-G-S-G-S-G-S-G-
S-G-S-G-S-G-S-G-S, as a negative control, were synthesized 
by Peptide Genetic Research Company (Livermore, CA, USA) 
as described previously [22].
Statistical analysis
Student’s t-test for unpaired values was used to determine 
the levels of significance. Analysis of variance (ANOVA) and a 
post hoc test (Dunnett’s method and Student-Newman-Keuls 
test) were employed when pair-wise multiple comparison 
procedures were necessary. Differences between means 
were considered significant at P<0.05.
Results
It can be seen in (Table 2) the total salivary IgA (Total IgA 
(μg/ml) in periodontitis patients: 164±19; healthy subjects: 
180±22; n=15 in each group) and its subtypes: IgA1 (μg/
ml): periodontitis patients: 66±5*; healthy subjects: 72±6; 
*P<0.0001 comparing with healthy subjects; n=15 in each 
group and IgA2 (μg/ml): periodontitis patients: 98±8*; healthy 
subjects: 108±9; *P<0.0001 comparing with healthy subjects; 
n=15 in each group. Also, the values of the salivary flow 
(Basal salivary flow (ml/10 min) in periodontitis patients: 
1.2±0.6*; healthy subjects: 9.7±3.5; *P<0.0001 comparing 
with healthy subjects; n=15 in each group) were performed 
with commercial plates for radial immunodiffusion containing 
anti-IgA.
The distribution of anti-β1-AR IgA was studied in clarified 
human whole saliva (CHWS) from untreated chronic peri- 
odontitis patients, treated withPPIT chronic severe perio-
dontitis patients and in healthy individuals (control). The 
scattergram of (Figure 1) shows that the optical density 
values (at 405 nm) of salivary anti-β1-AR IgA from CHWS 
of the untreated chronic severe periodontitis patients 
(periodontal CHWS) and those from  chronic severe 
periodontitis patients treated with PPIT. Also, the optical 
density values in healthy individuals (control CHWS) was 
shown. It can be seen that the data from periodontal CHWS and 
periodontal CHWS+PPIT were significantly higher (P<0.0001) 
than those of control CHWS. It is important to note that there 
is no significant difference between patients with chronic 
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periodontitis before and after PPIT in the amount of this 
autoantibody. On the other hand, the immunoreactivity of 
saliva fron untrated and treated patients were negative in the 
presence of non-related peptide (data not shown), asserting 
the immunological recognition of the anti-β1 AR IgA salivary 
only when the coating antigen is the synthetic β1 peptide.
(Figure 2) shows the distributions of PGE2 (A) and nitrite 
(B) concentrations in CHWS from untreated patients, treated 
patients and healthy individuals. As shown in the scatterogram 
of (Figure 2A), PGE2 concentrations were significantly higher 
in chronic periodontitis patients than that in control CHWS 
(P<0.0001). Moreover, the concentration of PGE2 in CHWS 
from untreated chronic periodontitis patients was statistically 
significantly higher than that from treated patients (P<0.001). 
It can be seen in (Figure 2B) that the concentration of nitrites 
Figure 1. Scatterogram showing values of IL-1β in clarified 
human whole saliva (CHWS) from healthy individuals 
(control), from untreated chronic periodontitis patients, 
and chronic periodontitis patients treated with periodontal I 
therapy (PPIT). Values are the mean ± SEM of 15 untreated 
and 15 treated periodontitis patients, and 15 healthy 
individuals as control. Dotted/dashed line, cut-off values 
0.009 (mean optical density (OD) ± 3 S.D. for controls); solid 
lines, median OD values.
Figure 2. Scattergram showing values of PGE2 and 
nitrites in clarified human whole saliva (CHWS) 
from healthy individuals (control), from untreated 
chronic periodontitis patients, and chronic treated 
periodontitis patients. (A) Distribution of the values 
of PGE2 (ng/ml) in CHWS from healthy individuals 
(control), from untreated chronic periodontitis 
patients, and treated chronic periodontitis patients. 
(B) Distribution of the values of nitrites (μM) in 
CHWS from healthy individuals (control) and from 
untreated chronic periodontitis patients, and treated 
chronic periodontitis patients. Values are mean ± 
SEM of 15 untreated and 15 treated periodontitis 
patients and 15 healthy individuals as control. 
Dotted/dashed line, cutoff values of 53.8 ng/ml for 
PGE2; solid lines, median PGE2 values; dotted/dashed 
line, cut off values of 6.01 μM for nitrites; solid lines, 
median nitrite values.
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in untreated patients were significantly increased when 
compared with control CHWS (P<0.0001) and the treated 
chronic periodontitis CHWS (P<0.001). The nitrite concentration 
from treated chronic periodontitis CHWS was not significantly 
different from that in the control group (P>0.05).
It can be seen in (Figure 3A) that the concentration of IL-1β 
in CHWS from untreated patients and patients treated with 
HBPT, the concentration was significantly higher that in normal 
individuals. Again, the levels of this cytokine in treated CHWS 
were significantly different from that in untreated patients.
We next investigated the level of MMP-3 in CHWS from the 
three different groups. Significant values were obtained in 
untreated and treated chronic periodontitis patients compared 
to healthy subjects (P<0.0001). Again, as shown above, MMP-3 
levels in untreated and treated chronic periodontitis patients 
were significantly different (P<0.001; (Figure 3B).
All of these findings are summarized in (Table 3), 
consistently indicating that the mean values of the different 
proinflammatory substances were significantly reduced after 
periodontal phase I therapy. But, the amount of anti-β1-AR 
IgA was not significantly different between untreated and 
treated chronic severe periodontitis patients.
(Figure 4) shows a positive correlation (r=0.05) between the 
increment of PGE2 production and MMP-3 concentrations in 
the function of the presence in the saliva of the anti-β1-AR. 
Discussion
The fair amount is known about the immunological 
mechanisms responsible for the pathology observed in the 
disease. The morphology of chronic periodontitis lesions, 
and the clinical signs and symptoms of the disease suggest 
that cytokines (IL-1β, PGE2) [23,24], nitric oxide levels [25] 
and cytoplasmic enzymes (MMP-3) [26] are important in the 
pathogenesis of the disorders. But, we considerer important to 
determine if the anti β1 adrenoceptor IgA present in the saliva 
of chronic severe patients, participates in the pathophysiology 
of the disease.
In this study we demonstrated high concentrations of IL-
Figure 3. Scattergram showing values of IL-1β and MMP-3 in 
clarified human whole saliva (CHWS) from healthy individu-
als (control) and from untreated chronic periodontitis patients 
treated with periodontal I therapy (PPIT) chronic periodonti-
tis patients. (A) Distribution of the values of IL-1β (pg/ml) in 
CHWS from healthy individuals (control) and from untreated 
chronic periodontitis patients, and chronic periodontitis 
patients treated with PPIT. (B) Distribution of the values of 
MMP-3 (ng/ml) in CHWS from healthy individuals (control) 
and from untreated chronic periodontitis patients treated with 
PPIT chronic periodontitis patients. Values are the mean ± 
SEM of 15 untreated and 15 treated periodontitis patients and 
15 healthy individuals as control. Dotted/dashed line, cutoff 
values of 610.9 pg/ml for IL-1β and solid lines; median IL-1β 
values; dotted/dashed line, cutoff values of 0.25 ng/ml for 
MMP-3; solid lines, median, MMP-3 values.
Groups anti-β1 IgA  
(OD 405 nm)
PGE2 (ng/ml) IL-1β (pg/ml) MMP-3
(ng/ml)
Healthy 
subjects
0.060±0,001 33.53±2,28 
 
237.90±35,34 0.153±0,019 
Untreated 
periodontitis 
patients
0.374±0,027* 333.12±18,64* 2528.00±76,01* 2.442±0,09*
Treated 
periodontitis 
patients
0.353±0.026 174.4±12.04* 1444.00±80.02 * 1.402±0.12*
Table 3. Mean values of the proinflammatory substances in whole 
human saliva.
Values expressed the means±SEM of fifteen patients and fifteen 
healthy normal subjects. *P<0.0001 comparing with healthy subjects.
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1β, PGE2, nitrites and MMP-3 in saliva from untreated chronic 
severe periodontitis patients. Moreover, the highest levels 
of IL-1β and PGE2 were found in the saliva of these patients 
compared with those detected in healthy individuals (control). 
Previously was demonstrated that in human gingival fibroblasts 
are able to produce large amounts of PGE2 in response to 
inflammatory cytokines, and the increased PGE2 would be 
a potent stimulator of bone resorption [27]. Macrophages, 
mononuclear cells and fibroblasts from gingival tissues and 
endothelial cells are responsible for the increase in IL-1β 
production [28]; thus, there is a close association between 
IL-1β levels and periodontal disease status. After periodontal 
based therapy in patients with chronic periodontitis, IL-1β 
levels are reduced in all patients tested, which is correlated 
with clinical improvement. PGE2 is thought to be involved in 
the pathogenesis of the oral lesions observed in untreated 
chronic periodontitis, because of its role as a potent stimulator 
of bone resorption and association with attachment loss was 
published [29]. Therefore, there is a reciprocal interaction 
between PGE2 and IL-1β; IL-1β is a potent stimulator of PGE2 
production in human gingival fibroblasts. However, PGE2 
differential regulates IL-1β-induced matrix metalloproteinase 
(MMP-3) production. In human gingival fibroblasts from 
healthy gingiva, PGE2 down-regulates IL-1β-induced MMP-3 
production, whereas in human gingival fibroblasts from 
periodontitis patients, PGE2 enhances it [29]. These data may 
reflect the heterogeneity of immuno-inflammatory responses 
in healthy and disease conditions, in which the concentrations 
of IL-1β, PGE2 MMP [30-31] may play a critical role as a marker 
of chronic severe periodontitis disease progression and oral 
manifestations.
The correlation between the amount of PGE2 and MMP-3 in 
the saliva of each patient studied in this study has demonstrated 
an important relationship with the amount of anti-β1 
IgA. Analysis of this result, PGE2 and MMP-3 performer on 
follow up studies underlines the correlation on the levels 
of the cytokine and the enzyme in the saliva of untreated 
patients with chronic periodontitis and the presence of 
salivary anti-β1 IgA. It is important to note that, as previously 
reported, the pathogenesis of periodontal disease involves 
essential immunologic factors associated with infections 
caused by bacteria in sub-gingival plaques. The level of nitrite 
in saliva and its increment in patients with untreated chronic 
periodontitis was observed, and also an increased expression 
of iNOS in periodontal disease biopsy samples as well as in 
gingival fibroblast cell culture was described [22,32]. NO levels 
are associated with the severity of periodontitis, allowing 
differentiation between moderate and advanced generalized 
chronic periodontitis and NO levels were correlated with 
probing depth [25].
The biological plausibility of the differences observed in 
this study indicated that nitric oxide levels may be important 
in the pathogenesis of the disorders, and may be only in partly 
explained, by periodontal bacterial components triggering 
the host-immune response and causing inflammation and 
activation of pro-inflammatory mediators (IL-1β, PGE2 and 
MMP-3). All of these molecules travelling in blood, together 
with those produced locally by the inflammatory process in the 
soft and hard oral tissues, might influence the pathophysiology 
of chronic periodontitis, but the real importance of the 
presence in the saliva of an anti β1 adrenoceptor IgA remain 
to be determined.
Figure 4. Correlation between the values of salivary anti-β-R 
IgA and PGE2 and MMP-3 concentrations in CHWS from 
untreated chronic periodontitis patients.
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Conclusions
The findings of the markedly elevated salivary IL-1β, PGE2 and 
MMP-3 levels and their significant reduction post therapy 
in patients with chronic periodontitis compared to healthy 
individuals (control), suggest a close association between 
salivary cytokines and enzymes and the periodontal status. But, 
the real participation of an anti β1 adrenoceptor IgA present 
in the saliva of patients with severe chronic periodontitis, 
incorporated another pathophysiological factor in this 
multifactorial disease was not clarified yet in this present 
work. Future longitudinal studies with larger sample sizes 
are needed to validate in saliva not only if IL-1β, PGE2 and 
MMP-3 are “real biomarkers” for periodontal disease but to 
know what role would play the autoantibody (β1 adrenoceptor 
IgA) present in the saliva of these patients in the course of 
the periodontal disease or in its pathophysiology.
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